PriceTargets.com logo

MiNK Therapeutics - INKT Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.50
  • Forecasted Upside: 1,140.46%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.52 As of 12/20/2024 06:51 PM ET
▲ +0.0238 (4.76%)

This chart shows the closing price for INKT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New MiNK Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INKT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INKT

Analyst Price Target is $6.50
▲ +1,140.46% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for MiNK Therapeutics in the last 3 months. The average price target is $6.50, with a high forecast of $9.00 and a low forecast of $4.00. The average price target represents a 1,140.46% upside from the last price of $0.52.

This chart shows the closing price for INKT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in MiNK Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
11/15/2024Robert W. BairdLower TargetOutperform ➝ Outperform$8.00 ➝ $4.00
10/9/2024HC WainwrightReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
8/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
5/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$9.00
3/21/2024HC WainwrightLower TargetBuy ➝ Buy$10.00 ➝ $9.00
8/10/2023HC WainwrightReiterated RatingBuy ➝ Buy$10.00
5/12/2023B. RileyReiterated RatingBuy
4/19/2023HC WainwrightReiterated RatingBuy$7.00
3/22/2023Evercore ISILower TargetOutperform$4.00 ➝ $3.00
3/22/2023HC WainwrightReiterated RatingBuy$7.00
8/10/2022HC WainwrightInitiated CoverageBuy$7.00
5/11/2022B. RileyLower Target$10.00 ➝ $7.00
1/24/2022B. RileyLower TargetBuy$24.00 ➝ $10.00
11/9/2021Evercore ISIInitiated CoverageOutperform$30.00
11/9/2021William BlairInitiated CoverageOutperform
11/9/2021B. RileyInitiated CoverageBuy$24.00
11/9/2021Robert W. BairdInitiated CoverageOutperform$26.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 0 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
MiNK Therapeutics logo
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Read More

Today's Range

Now: $0.52
Low: $0.48
High: $0.53

50 Day Range

MA: $0.69
Low: $0.46
High: $0.79

52 Week Range

Now: $0.52
Low: $0.46
High: $1.90

Volume

101,490 shs

Average Volume

85,920 shs

Market Capitalization

$20.72 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.1

Frequently Asked Questions

What sell-side analysts currently cover shares of MiNK Therapeutics?

The following equities research analysts have issued research reports on MiNK Therapeutics in the last twelve months: HC Wainwright, and Robert W. Baird.
View the latest analyst ratings for INKT.

What is the current price target for MiNK Therapeutics?

0 Wall Street analysts have set twelve-month price targets for MiNK Therapeutics in the last year. Their average twelve-month price target is $6.50, suggesting a possible upside of 1,140.5%. HC Wainwright has the highest price target set, predicting INKT will reach $9.00 in the next twelve months. Robert W. Baird has the lowest price target set, forecasting a price of $4.00 for MiNK Therapeutics in the next year.
View the latest price targets for INKT.

What is the current consensus analyst rating for MiNK Therapeutics?

MiNK Therapeutics currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe INKT will outperform the market and that investors should add to their positions of MiNK Therapeutics.
View the latest ratings for INKT.

What other companies compete with MiNK Therapeutics?

Other companies that are similar to MiNK Therapeutics include Rani Therapeutics, Assertio, Anixa Biosciences, Adagene and PowerUp Acquisition. Learn More about companies similar to MiNK Therapeutics.

How do I contact MiNK Therapeutics' investor relations team?

The company's listed phone number is 212-994-8250 and its investor relations email address is [email protected]. The official website for MiNK Therapeutics is www.minktherapeutics.com. Learn More about contacing MiNK Therapeutics investor relations.